Ward William G, Gautreaux Michael D, Lippert Dylan C, Boles Carol
Department of Orthopaedics, Wake Forest University Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC 27157-1070, USA.
Clin Orthop Relat Res. 2008 Aug;466(8):1837-48. doi: 10.1007/s11999-008-0294-4. Epub 2008 May 28.
Achieving union between host bone and massive structural allografts can be difficult. Donor and recipient human leukocyte antigen (HLA) mismatches and recipient antibody response to donor HLA antigens might affect union. In a prospective multiinstitutional study, we enrolled a consecutive series of patients receiving cortex-replacing, massive structural bone allografts to determine the rate of donor-specific HLA antibody sensitization and to investigate the potential effect of such HLA alloantibody sensitization on allograft incorporation. HLA typing of patients and donors was determined by molecular typing methods. Donor-specific HLA sensitization occurred in 57% of the patients but had no demonstrable effect on graft incorporation or union. The type of host-allograft junction did have a major effect on graft incorporation. Cortical-to-cortical allograft-to-host junctions healed more slowly (mean, 542 days) than corticocancellous to corticocancellous allograft-to-host junctions (mean, 243 days). Although HLA sensitization does not appear to delay structural allograft bone incorporation, further followup is required to determine if there is an association between HLA sensitization and long-term graft survival. Based on these preliminary data, measures to further minimize or modulate HLA sensitization or response are not indicated at present for the purposes of improving structural bone allograft union.
Level II, prognostic study.
实现宿主骨与大块结构性同种异体骨的愈合可能具有挑战性。供体和受体人类白细胞抗原(HLA)不匹配以及受体对供体HLA抗原的抗体反应可能会影响愈合。在一项前瞻性多机构研究中,我们纳入了一系列连续接受皮质替代型大块结构性骨同种异体移植的患者,以确定供体特异性HLA抗体致敏率,并研究这种HLA同种异体抗体致敏对同种异体骨植入的潜在影响。患者和供体的HLA分型通过分子分型方法确定。57%的患者发生了供体特异性HLA致敏,但对移植物植入或愈合没有明显影响。宿主-同种异体骨连接处的类型对移植物植入有重大影响。皮质对皮质的同种异体骨与宿主连接处的愈合比皮质骨松质对皮质骨松质的同种异体骨与宿主连接处愈合更慢(平均为542天对243天)。虽然HLA致敏似乎不会延迟结构性同种异体骨的植入,但需要进一步随访以确定HLA致敏与移植物长期存活之间是否存在关联。基于这些初步数据,目前为改善结构性骨同种异体骨愈合而采取进一步减少或调节HLA致敏或反应的措施并无必要。
II级,预后研究。